COPENHAGEN, Feb 24 (Reuters) – Danish drugmaker Novo Nordisk said on Tuesday it plans to slash the U.S. list prices of its blockbuster weight-loss drug Wegovy and diabetes drug Ozempic by up to 50% and 35% respectively as of January next year.
(Reporting by Louise Rasmussen, editing by Terje Solsvik)
Comments